Manglani Ravi, Landaeta Maria, Maldonado Marcelo, Hoge Gregory, Basir Riyad, Menon Vidya
Division of Pulmonary, Critical Care, and Sleep Medicine, Westchester Medical Center, Valhalla, NY, USA.
Department of Medicine, Lincoln Medical and Mental Health Center, Bronx, NY, USA.
J Community Hosp Intern Med Perspect. 2021 Sep 20;11(5):727-732. doi: 10.1080/20009666.2021.1955448. eCollection 2021.
: The use of Non-Invasive Ventilation (NIV) in acute asthma exacerbation remains controversial. Comparative data on patient characteristics that benefit from NIV in asthma exacerbation to those patients that fail NIV remains limited. Our study compares some of these patient characteristics and examines if NIV is safe and effective in carefully selected patients. : Following institutional review board approval, we extracted from the electronic medical record and conducted a retrospective chart-based review of those patients who received NIV in the emergency room for a diagnosis of asthma exacerbation from January 2017 to December 2018. : The rate of failure of NIV overall was low, at 9.17%, with younger patients more likely to fail NIV (P = 0.03) and need invasive mechanical ventilation. Surprisingly, baseline asthma severity did not impact NIV failure rate, and neither did body mass index, smoking history, and a host of clinical characteristics. Understandably, the length of stay was significantly longer in the group of patients that failed NIV. There were no adverse events, such as an increased rate of barotrauma events in either group. In conclusion, this study contributes to the growing body of evidence that NIV is a safe and effective adjunct to routine care in the management of patients with asthma exacerbation.
无创通气(NIV)在急性哮喘加重期的应用仍存在争议。关于在哮喘加重期从NIV中获益的患者特征与NIV治疗失败的患者特征的比较数据仍然有限。我们的研究比较了其中一些患者特征,并研究了NIV在精心挑选的患者中是否安全有效。:在获得机构审查委员会批准后,我们从电子病历中提取数据,并对2017年1月至2018年12月在急诊室接受NIV治疗且诊断为哮喘加重的患者进行了基于图表的回顾性研究。:NIV总体失败率较低,为9.17%,年轻患者更有可能NIV治疗失败(P = 0.03)并需要有创机械通气。令人惊讶的是,基线哮喘严重程度并未影响NIV失败率,体重指数、吸烟史及一系列临床特征也未产生影响。可以理解的是,NIV治疗失败的患者组住院时间明显更长。两组均未出现不良事件,如气压伤事件发生率增加。总之,本研究为越来越多的证据提供了补充,即NIV是哮喘加重期患者常规治疗中一种安全有效的辅助治疗方法。